We are a quantum physics-based, AI-powered drug R&D company with the mission to revolutionize drug discovery and development by improving the speed, scale, novelty and success rate. With operations in both China and the U.S., we strive to deploy the best capabilities and resources available to us in each market to meet the needs of our customers and collaborators.
Beyond our team’s domain expertise and creative thinking, the key to our mission is the integrated technology platform, which combines the mutually informing and reinforcing cloud supercomputing-powered in silico tools and our wet lab with robotic automation, and enables discovery and development of innovative therapeutics at a pace and scale beyond traditional alternatives. We are among the pioneering AI-powered drug R&D companies in the world that have established a platform with an iterative feedback loop between quantum physics-based dry lab and wet lab capabilities, according to Frost & Sullivan.
With our platform designed to improve dry lab calculations with experimental data generated by the wet lab and enhance the efficiency of the wet lab by insights derived from dry lab calculations, we believe that we are well positioned at this moment where the combination of AI, computing power, data and automation is becoming increasingly critical for pharmaceutical development.
Since our founding, we have received investments and support from world-renowned investors, and we believe this blue-chip shareholder base is a testament to our capabilities and prospects.
Location: United States, Massachusetts, Cambridge
Employees: 201-500
Total raised: $380M
Founded date: 2014
Investors 3
Date | Name | Website |
- | Taihill Ve... | taihill.vc |
06.09.2022 | Skylight I... | skylightin... |
23.02.2022 | 5Y Capital | 5ycap.com |
Funding Rounds 3
Date | Series | Amount | Investors |
29.09.2020 | Series C | $319M | - |
29.10.2018 | Series B | $46M | - |
23.01.2018 | Series B | $15M | - |
Mentions in press and media 35
Date | Title | Description | Source |
11.03.2024 | Artificial Intelligence in Healthcare Market Size, Share And... | Artificial Intelligence In Healthcare Global Market Report 2024 – Market Size, Trends, And Global Fo... | einpresswi... |
30.01.2024 | XtalPi Unveils Ailux: A New Chapter in AI-Powered Biologics ... | CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- XtalPi Inc. (XtalPi), a globally leading innovative ... | en.prnasia... |
27.11.2023 | XtalPi and HKU's Advanced Biomedical Instrumentation Centre ... | CAMBRIDGE, Mass., Nov. 27, 2023 /PRNewswire/ -- XtalPi Inc. (XtalPi) and the Advanced Biomedical Ins... | en.prnasia... |
31.05.2023 | XtalPi Announces Collaboration with Lilly, Using AI + Roboti... | XtalPi Inc., a pioneering pharmaceutical technology company powered by artificial intelligence (AI) ... | aithority.... |
30.05.2023 | Sequoia China-Backed AI Startup Xtalpi To Partner With Pharm... | Ma Jian, cofounder and CEO of Xtalpi.Xtalpi | forbes.com... |
20.12.2022 | XtalPi and EDDC collaborate in AI-empowered Drug Discovery p... | XtalPi, a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and a... | aithority.... |
25.11.2022 | XtalPi and CK Life Sciences to collaborate in AI-empowered t... | AI-driven drug research and development (R&D) is breaking new ground, providing faster and more ... | einpresswi... |
27.10.2022 | US sanctions on China could extend to biotech, official says | On the heels of the Biden administration’s decision to impose sweeping chip sanctions on China, ther... | techcrunch... |
19.01.2022 | XtalPi Partners with Excelra for GOSTAR to Enhance its Intel... | HYDERABAD, India and SHENZHEN, China, Jan. 19, 2022 /PRNewswire/ -- Excelra, a leading global Data &... | en.prnasia... |
04.10.2021 | 2021 is already a record breaking year for digital health fu... | Funding to digital health companies surpassed $20 billion for the first time ever COVID has taken di... | vator.tv/n... |
Show more